Psoriasis Vulgaris
Conditions
Interventions
None listed
Sponsors
Ishitsuka Yosuke
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Group with psoriasis vulgaris patients Patients with psoriasis vulgaris who are scheduled to receive, or are currently receiving, biologics. Subjects over the age of 18 at the time of informed consent. Subjects who have provided written informed consent for participation in this study. 2) Healthy volunteer group Subjects over the age of 18 at the time of informed consent. Subjects who have provided written informed consent for participation in this study.
Exclusion criteria
Exclusion criteria: 1) Group with psoriasis vulgaris patients Subjects with a history of serious systemic diseases that the investigator have considered inappropriate for participation in this study. Subjects who have received phototherapy (UVB/PUVA) within the month prior to enrollment. Subjects who have applied topical medications (including prescription and over-the-counter drugs) to the skin sampling site on the day of sample collection. Subjects for whom skin sampling is deemed difficult due to wounds or other conditions at the sampling site, as determined by the principal investigator or co-investigators. Subjects who are pregnant or currently breastfeeding and who may be pregnant. Subjects considered inappropriate for the study by the principal investigator or co- investigators of the clinical research. 2) Healthy volunteer group Presence of any disease requiring treatment. Subjects with a history of psoriasis vulgaris. Subjects with a history of atopic dermatitis within the 2 years. Subjects with a history of serious systemic diseases that the investigator have considered inappropriate for participation in this study. Subjects who have applied topical medications (including prescription and over-the-counter drugs) to the skin sampling site on the day of sample collection. Subjects for whom skin sampling is deemed difficult due to wounds or other conditions at the sampling site, as determined by the principal investigator or co-investigators. Subjects who are pregnant or currently breastfeeding and who may be pregnant. Subjects considered inappropriate for the study by the principal investigator or co- investigators of the clinical research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A comparative analysis of the pathological evaluation, skin epigenetic modification, skin transcriptome, suction blister fluid proteome, and blood proteome will be conducted to identify distinct molecular signatures. | — |
Contacts
Public ContactYosuke Ishitsuka
The University of Osaka Hospital
Outcome results
None listed